Related Experiment Videos
Riluzole therapy in cervical dystonia
Jörg Müller1, Gregor K Wenning, Jörg Wissel
1Department of Neurology, Innsbruck University Hospital, Innsbruck, Austria.
Summary
Riluzole shows promise for treating cervical dystonia (CD) refractory to other treatments. This pilot study found significant improvements in CD symptoms, suggesting potential benefits for specific patient subgroups.
Area of Science:
- Neurology
- Pharmacology
Background:
- Cervical dystonia (CD) is a debilitating movement disorder.
- Patients refractory to botulinum toxin A and oral treatments have limited therapeutic options.
Purpose of the Study:
- To evaluate the efficacy of riluzole in patients with cervical dystonia refractory to standard treatments.
Main Methods:
- A 6-week open-label pilot study.
- Six patients with refractory cervical dystonia were treated with riluzole (50 mg twice daily).
- Outcomes were assessed using the Tsui rating scale with blinded video rating.
Main Results:
- Significant improvement in the Tsui rating scale scores (P = 0.002).
- Over 50% of patients experienced a >30% improvement in Tsui score.
- A >50% reduction in head tremor/jerk subscore was observed in responders.
Conclusions:
- Riluzole may be a viable treatment option for a subset of cervical dystonia patients.
- Further investigation is warranted for refractory cervical dystonia cases.